Influenza A Virus, H5N1 Subtype Infections-Pipeline Review, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline Review, H2 2017


  • Products Id :- GMDHC9685IDB
  • |
  • Pages: 151
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Influenza A Virus, H5N1 Subtype Infections-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections-Pipeline Review, H2 2017, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.

H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 11, 1, 31 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Influenza A Virus, H5N1 Subtype Infections-Overview

Influenza A Virus, H5N1 Subtype Infections-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Influenza A Virus, H5N1 Subtype Infections-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Influenza A Virus, H5N1 Subtype Infections-Companies Involved in Therapeutics Development

Akshaya Bio Inc

Altimmune Inc

Antigen Express Inc

Aphios Corp

BiondVax Pharmaceuticals Ltd

CEL-SCI Corp

Cocrystal Pharma Inc

Curevac AG

Gemmus Pharma Inc

GlaxoSmithKline Plc

Hemispherx Biopharma Inc

iBio Inc

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kineta Inc

Lakewood-Amedex Inc

Medicago Inc

Medigen Vaccine Biologics Corp

Microbiotix Inc

NanoBio Corp

Nanotherapeutics Inc

NanoViricides Inc

OPKO Health Inc

PaxVax Inc

PeptiDream Inc

Shionogi & Co Ltd

Takeda Pharmaceutical Company Ltd

TechnoVax Inc

Vaxart Inc

Vaxine Pty Ltd

Visterra Inc

Influenza A Virus, H5N1 Subtype Infections-Drug Profiles

A-06-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AE-AI vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alferon LDO-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APP-0205-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APP-309-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-301-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

beraprost sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-42344-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEL-1000-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CHOS-05-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPC-005-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gamma-Flu-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GP-1002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GP-1681-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GREFLU/VIE-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HAI-05-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-36.6-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Influ-nRNA-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] (split virion) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] (virus like particle) vaccine 2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine 2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H5N1] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H5N1 + A/H1N1] (trivalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H5N1 + A/H1N1] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H5N1 + A/H5N2 + A/H7N2 + A/H7N3 + A/H9N2] (virus like particle) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-3510-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIN-1148-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lalistat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MBX-2329-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MBX-2546-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Hemagglutinin for Avian Infection and Swine Flu Infection-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Neuraminidase for Influenza A Virus H1N1 and H5N1 Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MV-4-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nasovax-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Influenza Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pimodivir hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PNSIA-28-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PNSIA-49-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXVX-0103-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-033188-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Influenza A Virus H1N1 and H5N1 Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Sirtuin for Influenza-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Influenza, HSV and HIV Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Viral Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TVX-003-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VGX-3400X-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VH-244-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIS-410-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Influenza A Virus, H5N1 Subtype Infections-Dormant Projects

Influenza A Virus, H5N1 Subtype Infections-Discontinued Products

Influenza A Virus, H5N1 Subtype Infections-Product Development Milestones

Featured News & Press Releases

Apr 24, 2017: Shionogi Presents New Clinical and Non-clinical Data on S-033188, an Investigational Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases

Apr 17, 2017: Shionogi to Present New Data on S-033188, a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases

Sep 01, 2016: Abzyme Awarded Highly Competitive National Institutes of Health Phase II SBIR Grant

Jun 01, 2016: NanoBio To Present Data Demonstrating Benefit Of Its Intramuscular Nanoemulsion Pandemic Influenza Vaccine

Mar 22, 2016: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress

Sep 30, 2015: BiondVax Initiates a Phase IIb Clinical Trial in Europe for its Universal Flu Vaccine for Pandemic Outbreak

Jun 02, 2015: Visterra Announces Presentation of Data at International Influenza Meeting on the Efficacy of VIS410 for Treatment of a Deadly Strain of Avian Influenza

Mar 23, 2015: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress in Washington D.C.

Oct 29, 2014: BiondVax Receives Approvals for Patent in Europe and Japan for its Universal Flu Vaccine

Mar 24, 2014: Valneva Announces the First Ever Marketing Authorization for a Human Vaccine Produced in the EB66 Cell Line

Feb 17, 2014: BiondVax will Present Clinical Results and the Company's Strategy for Pandemic Preparedness Ahead of Flu Outbreak at the World Health Organization's Key Influenza Meeting

Feb 10, 2014: BiondVax Receives Patent Registration Approval for Multimeric Multiepitope Influenza Vaccines in Hong Kong as well as Allowance of Patent Registration in US for the Companys Universal Flu Vaccine

Jan 21, 2014: BiondVaxs universal flu vaccine matches all 6 potentially pandemic flu strains in the world today: H5N1, H5N8, H6N1, H7N 7 , H7N 9 and H10N8

Oct 03, 2013: BiondVax is a member of the UNISEC consortium awarded a European Commission FP7 grant of 6 million EURO

Sep 09, 2013: Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains with Pandemic Potential

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

List of Tables

Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Akshaya Bio Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Altimmune Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Antigen Express Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Aphios Corp, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by BiondVax Pharmaceuticals Ltd, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by CEL-SCI Corp, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Cocrystal Pharma Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Curevac AG, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Gemmus Pharma Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by GlaxoSmithKline Plc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Hemispherx Biopharma Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by iBio Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Inovio Pharmaceuticals Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Johnson & Johnson, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Kineta Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Lakewood-Amedex Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Medicago Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Medigen Vaccine Biologics Corp, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Microbiotix Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by NanoBio Corp, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Nanotherapeutics Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by NanoViricides Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by OPKO Health Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by PaxVax Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by PeptiDream Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Shionogi & Co Ltd, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by TechnoVax Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Vaxart Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Vaxine Pty Ltd, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Pipeline by Visterra Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Dormant Projects, H2 2017

Influenza A Virus, H5N1 Subtype Infections-Dormant Projects, H2 2017 (Contd..1), H2 2017

Influenza A Virus, H5N1 Subtype Infections-Dormant Projects, H2 2017 (Contd..2), H2 2017

Influenza A Virus, H5N1 Subtype Infections-Dormant Projects, H2 2017 (Contd..3), H2 2017

Influenza A Virus, H5N1 Subtype Infections-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Akshaya Bio Inc

Altimmune Inc

Antigen Express Inc

Aphios Corp

BiondVax Pharmaceuticals Ltd

CEL-SCI Corp

Cocrystal Pharma Inc

Curevac AG

Gemmus Pharma Inc

GlaxoSmithKline Plc

Hemispherx Biopharma Inc

iBio Inc

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kineta Inc

Lakewood-Amedex Inc

Medicago Inc

Medigen Vaccine Biologics Corp

Microbiotix Inc

NanoBio Corp

Nanotherapeutics Inc

NanoViricides Inc

OPKO Health Inc

PaxVax Inc

PeptiDream Inc

Shionogi & Co Ltd

Takeda Pharmaceutical Company Ltd

TechnoVax Inc

Vaxart Inc

Vaxine Pty Ltd

Visterra Inc

Influenza A Virus, H5N1 Subtype Infections Therapeutic Products under Development, Key Players in Influenza A Virus, H5N1 Subtype Infections Therapeutics, Influenza A Virus, H5N1 Subtype Infections Pipeline Overview, Influenza A Virus, H5N1 Subtype Infections Pipeline, Influenza A Virus, H5N1 Subtype Infections Pipeline Assessment

select a license
Single User License
USD 2000 INR 140000
Site License
USD 4000 INR 280000
Corporate User License
USD 6000 INR 420000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com